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BACKGROUND: Opioids can suppress testosterone in men, which can lead to extensive morbidity. Identi-
fying risk factors for androgen deﬁciency in men using daily opioids could improve monitoring and safety.
METHODS: In a retrospective cohort study,weusedKaiser PermanenteNorthernCalifornia databases to identify
men on stable doses of opioids. These subjects had no diagnoses of cancer or endocrine disorders except treated
primary hypothyroidism. Subjects were divided into those using long-acting opioids and short-acting opioids.
Total testosterone wasmeasured in blood drawn in themorningwhile the subjects were on their regular dose of
opioid. The association between opioid duration of action and androgen deﬁciency, controlling for dose, body
mass index, age, diabetes, hyperlipidemia, and hypertension, was assessed using logistic regression.
RESULTS: The study included 1585 men. Men on long-acting opioids were more likely to be androgen
deﬁcient than men on short-acting opioids (57% vs 35%, P < 0.001; odds ratio [OR] 3.39; 95% conﬁdence
interval [CI], 2.39-4.77). As dose increased, the odds of androgen deﬁciency increased; however, dose was
more strongly associated with androgen deﬁciency in men on short-acting opioids (OR 1.16; 95% CI, 1.09-
1.23, for each 10-mg increase in dose) than in men on long-acting opioids (OR 1.01; 95% CI, 1.01-1.02).
CONCLUSION: Use of long-acting opioids is a key risk factor in the development of androgen deﬁciency.
Dose was signiﬁcantly associated with androgen deﬁciency, but more so for men on short-acting than on
long-acting opioids.
 2014 The Authors. Published by Elsevier Inc. All rights reserved.  The American Journal of Medicine
(2014) 127, 1195-1201
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0Short-acting opioid; TestosteroneOpioids remain a cornerstone of treatment for many types
of pain, including chronic pain and cancer pain. For the last
2 decades, the belief has been that opioids could be used
safely and effectively in selected patients with appropriate
monitoring for abuse and diversion and minimal moni-
toring for side effects such as respiratory depression and
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.1016/j.amjmed.2014.07.015Low testosterone or androgen deﬁciency is a common
consequence of opioid use that has been documented since
the 1970s in men on methadone for maintenance therapy.1,2
More recently, it has been documented that opioid use is
associated with androgen deﬁciency in men with chronic
pain,3,4 although factors contributing to this deﬁciency have
not been elucidated. In our recent cohort study of 81 men
from a chronic pain clinic within Kaiser Permanente
Northern California (KPNC), we found that, controlling for
morphine standardized equivalent dose (MSE), long-acting
opioids were associated with signiﬁcantly higher odds of
androgen deﬁciency than were short-acting opioids (odds
ratio [OR] 4.78; 95% conﬁdence interval, 1.51-15.07).5
Androgen deﬁciency has serious and expensive health
consequences. It can cause muscle loss, fatigue, loss of
libido, and erectile dysfunction and can lead to decreased
bone density, osteoporosis, and increased fracture risk.6-8
Additionally, androgen deﬁciency may be involved in thell rights reserved.
1196 The American Journal of Medicine, Vol 127, No 12, December 2014development of cardiovascular disease.9 Thus, androgen
deﬁciency may result in increased risk to patients, decreased
quality of life, and potentially increased use of resources to
treat sequelae.
The goal of this larger study of a predominately primary
care population of men on opioids was to further examineCLINICAL SIGNIFICANCE
 Long-acting opioids are associated withthe association between the dura-
tion of action of opioids and the
risk of development of androgen
deﬁciency.signiﬁcantly more risk of androgen
deﬁciency in men than equivalent doses
of short-acting opioids.
 Higher opioid dose is associated with
increased androgen deﬁciency, but more
so for short-acting opioids than for long-
acting opioids.
 These ﬁndings hold true when control-
ling for markers of metabolic syndrome.METHODS
This retrospective cohort study of
1585 men was conducted within
KPNC, a large integrated health
care delivery system providing
care for more than 3.2 million
members in San Francisco and the
surrounding Bay Area. Electronic
data on demographics, outpatient
and inpatient diagnoses and pro-
cedures, and pharmacy and labo-
ratory utilization were collected for all study subjects. The
Kaiser Foundation Research Institute’s Institutional Review
Board approved this study with waiver of consent.
Study subjects were men ages 18 to 80 years with at least
one total testosterone level measurement performed from
January 1, 2007 to December 31, 2011 and who had been
dispensed opioid prescriptions demonstrating continuous
opioid use. For this study, continuous opioid use was
deﬁned as having an opioid possession rate of 90 days’
supply during the 100 days before the date on which serum
total testosterone was measured. The study index date was
the date of the blood draw for serum total testosterone
measurement.Opioids and Duration of Action
For the purposes of this study, opioids were deﬁned as either
long acting or short acting. Long-acting opioids were those
formulated to provide at least 8 hours of analgesia; some
long-acting opioids such as methadone are inherently long
acting, whereas others are formulated as controlled-release
(CR) or sustained-release (SR) versions of short-acting
opioids. The fentanyl patch was considered a long-acting
opioid. Short-acting opioids were deﬁned as immediate-
release medications providing analgesia for 6 hours or less.5
Subjects taking more than 2 different opioids in the study
period were excluded, as we did not consider them to be on
a stable opioid regimen during the study time frame. Sub-
jects included in the study were taking opioids prescribed in
one of 2 possible patterns:
1. Subjects were taking exactly one of the following opi-
oids: codeine; hydrocodone; hydromorphone; fentanyl;
methadone; long-acting morphine in the form of either
morphine CR or morphine SR; or oxycodone in either along-acting formulation (oxycodone SR) or a short-
acting, immediate-release formulation (oxycodone IR).
2. Subjects were taking exactly one long-acting opioid
(fentanyl, methadone, morphine CR or SR, or oxycodone
SR) plus exactly one short-acting opioid (codeine,
hydrocodone, hydromorphone, or oxycodone IR).From our clinical experience,
we assumed that subjects taking
one long-acting opioid plus one
short-acting opioid were taking
the short-acting opioid for break-
through pain.
Subjects taking buprenorphine,
tramadol, or propoxyphene during
the study period were excluded
either due to inability to accurately
calculate MSE or because they
were used for reasons other than
chronic pain, such as chemical
dependency. Subjects having am-
bulatory pharmacy records of ste-
roid, supplemental testosterone, orandrogen use in the 3 years before measurement of testos-
terone were excluded from the study. Furthermore, subjects
with an inpatient or outpatient diagnosis of any the following
conditions in the 3 years before the testosterone measurement
also were excluded: pituitary abnormalities, sarcoidosis,
Kallmann syndrome, histiocytosis, Klinefelter syndrome,
hemochromatosis, malignant neoplasm, or renal disease.
Men were classiﬁed as being on short-acting opioids if
they were on exactly one short-acting opioid. Men were
classiﬁed as being on long-acting opioids if they were on
either exactly one long-acting opioid or one long-acting
opioid and one short-acting opioid. Androgen deﬁciency
was deﬁned as total testosterone <250 ng/dL in a blood
sample drawn before 10 AM. The upper limit of 250 ng/dL
was chosen based upon the speciﬁc assay used within
KPNC. Total testosterone, rather than free and total testos-
terone, was chosen based upon KPNC endocrinology
guidelines and the recommendations of the Endocrine
Society.10 Laboratory evaluations of total testosterone were
determined using a Siemens Immulite 2000 (Siemens,
Munich, Germany) testosterone assay (coefﬁcient of varia-
tion 9.6% at 149 ng/dL and 11.1% at 521 ng/dL).Calculation of MSE
Daily dose for a single purchased opioid was calculated and
converted to an MSE using the following formula:11
MSE ¼ðOpioid strengthÞ  ðNumber of pills per doseÞ
 ðNumber of doses dailyÞ
 ðMorphine standardized equivalent coefficientÞ
The MSE for subjects on short-acting medications was
deﬁned as the MSE corresponding to the opioid purchased
Rubinstein and Carpenter Risk Factors for Opioid-Induced Androgen Deﬁciency 1197immediately before the index date. If the dispensed quantity
was <25% of the dispensed quantity of the previous pre-
scription, then the MSE associated with the larger dispensed
quantity was considered to be the MSE. The rationale for
this choice was that this change in dose was probably a
short-term additional prescription for acute pain to be used
on top of the baseline dose rather than a sudden decrease in
the chronic dose. Charts of subjects on only long-acting
medications were abstracted by hand. For patients on both
long- and short-acting opioids, the MSE equal to the most
recently purchased long-acting opioid was added to the
MSE corresponding to the most recently purchased short-
acting opioid. Medical record review was performed on
232 subjects (14.6%) to verify MSE calculations.Comorbidities
The constellation of conditions that make up metabolic
syndrome have been shown to be associated with androgen
deﬁciency.12-15 Four of the conditions associated with
metabolic syndrome were included in our study as potential
confounders: diabetes, hyperlipidemia, hypertension, and
obesity. Evidence of metabolic syndrome-associated con-
founders was extracted for each study subject. Subjects with
a record of diabetes in the KPNC Division of Research
Diabetes Registry16 at any point before the index date were
counted as diabetics. The KPNC Chronic Conditions Man-
agement databases were used to identify hypertension in the
calendar year before the index date. Subjects having inpa-
tient or outpatient diagnoses indicating hyperlipidemia in
the year before index date were considered to have hyper-
lipidemia. The most recent body mass index (BMI) in the
180 days before the index date was collected; obesity was
deﬁned as BMI 30.17 Subjects having any statins
dispensed in the outpatient setting in the year before the
index date were considered statin users.Table 1 Population Characteristics by Study Group
Characteristic
Short-acting
Opioids n ¼ 969
Long-acting
Opioids n ¼ 616
Age, median (IQR) 54 (46-61) 54 (46.5-61)
Dose, median (IQR) 30 (20-40) 150 (90-251.25)Statistical Methods
Univariate summary values for categorical variables are
reported as frequencies and proportions and for continuous
variables as medians with interquartile ranges (IQRs, 25th
and 75th percentile). Bivariate analyses of binomial vari-
ables were performed using the chi-squared test. Bivariate
analyses of the continuous variables MSE and age were
performed using the Wilcoxon-Mann-Whitney nonpara-
metric test. Multivariable analyses were performed using
logistic regression. The product of the independent variables
duration of action and MSE was added to the logistic
regression model to test for interaction.Obese,* n (%) 257 (42.6%) 440 (46.8%)
Diabetes, n (%) 172 (17.8%) 107 (17.4%)
Hypertension, n (%) 362 (58.8%) 574 (59.2%)
Hyperlipidemia, n (%) 393 (40.6%) 210 (34.1%)
Statin use, n (%) 351 (36.2%) 201 (32.6%)
IQR ¼ interquartile range.
*Body mass index data on 42 subjects missing.RESULTS
Patient Characteristics
There were 1585 men who met the inclusion criteria for
the study; 616 chronically used long-acting opioids in the
90 days before testosterone was measured, and 969 usedshort-acting opioids (Table 1). In a bivariate analysis, men
who used long-acting opioids were more likely to be
androgen deﬁcient (n ¼ 351, 57.0%) than men on short-
acting opioids (n ¼ 340, 35.1%, P < .001; Table 2). Men
with diabetes, hypertension, or hyperlipidemia; taking
statins; or with a BMI 30 were more likely to have
androgen deﬁciency than men without these conditions
(Table 2).
The median MSE for androgen-deﬁcient men was 60 mg
(IQR 30-165); the median MSE for men who were not
androgen deﬁcient was 40 mg (IQR 20-70, P < .001). Age
as a continuous variable was not signiﬁcantly different be-
tween androgen-deﬁcient men (median 54 [IQR 47e61])
and men who were not androgen deﬁcient (median 54 [IQR
46e61], P ¼ .11).Duration of Action
Preliminary analyses of our dataset showed that diabetes,
hyperlipidemia, hypertension, and age were highly corre-
lated with each other. To avoid multicollinearity in the
multivariable analyses, we created a combined variable
summarizing all 4 of these patient characteristics. Each
subject was given a count of metabolic syndromee
associated conditions (diabetes, hyperlipidemia, and hyper-
tension) combined with age categorized as <50 or 50
years. Statin use was not included as an independent vari-
able in our multivariable models because it was too highly
correlated with diabetes, hyperlipidemia, and hypertension.
In a logistic regression analysis, subjects on long-acting
opioids had 3.39 times the odds of having androgen deﬁ-
ciency than patients exclusively on short-acting opioids after
controlling for MSE, obesity, and a count of the conditions
associated with metabolic syndrome (diabetes, hyperlipid-
emia, and hypertension) stratiﬁed by age (95% conﬁdence
interval, 2.39-4.77; Table 3).Dose
In preliminary analyses, duration of action and dose showed
signiﬁcant interaction. The risk associated with dose was
therefore reported for each level of MSE, holding duration
of action constant (Table 3). Dose had a greater effect in
Table 2 Unadjusted Rates of Androgen Deﬁciency According to Patient Risk Factors
Not Androgen Deﬁcient
Androgen Deﬁcient
(Total Testosterone  250 ng/dL) P Value*
Duration of action of opioid
Long (n ¼ 616) 265 (43.0%) 351 (57.0%) <.001
Short (n ¼ 969) 629 (64.9%) 340 (35.1%)
Obese†
Obese 318 (45.6%) 379 (54.4%) <.001
Not obese 551 (65.1%) 295 (34.9%)
Diabetes
Diabetes 125 (44.8%) 154 (55.2%) <.001
No diabetes 769 (58.9%) 537 (41.1%)
Hypertension
Hypertension 481 (51.4%) 455 (48.6%) <.001
No hypertension 413 (63.6%) 236 (36.4%)
Hyperlipidemia
Hyperlipidemia 310 (51.4%) 293 (48.6%) .002
No hyperlipidemia 584 (59.5%) 398 (40.5%)
Statins
Statins use 256 (46.4%) 296 (53.6%) <.001
No statins use 638 (61.8%) 395 (38.2%)
*Chi-squared test.
†Body mass index values were missing for 42 subjects.
Table 3 Adjusted Odds Ratios for Androgen Deﬁciency*
Odds
Ratio
95% Conﬁdence
Interval
Duration of action
Long (vs short) 3.39 2.39-4.77
Dose (MSE)
Total MSE (10 mg) duration ¼ short 1.16 1.09-1.23
Total MSE (10 mg) duration ¼ long 1.01 1.01-1.02
Obese
Obese vs not obese 2.22 1.78-2.77
Missing vs not obese 1.51 0.77-2.89
Number of conditions by age†
(referent: 0 conditions, <50 years old)
0 conditions, 50 0.91 0.60-1.36
1 condition, <50 1.50 1.00-2.26
1 condition, 50 1.34 0.95-1.90
2 conditions, <50 1.43 0.81-2.51
2 conditions, 50 1.95 1.36-2.79
3 conditions, <50 1.21 0.52-2.77
3 conditions, 50 2.59 1.64-4.12
MSE ¼ morphine standardized equivalent dose.
*The model was adjusted for MSE, obesity, and a count of the
following conditions stratiﬁed by age: diabetes, hyperlipidemia, and
hypertension.
†The number of conditions is a count of the number of comorbidities
present (diabetes, hypertension, hyperlipidemia) stratiﬁed by age < 50
and age >50 years.
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androgen deﬁciency of 1.16 for every 10-mg increase in
MSE) than in men taking long-acting opioids (increase in
the OR of 1.01 for every 10-mg increase in MSE). Having 2
or 3 metabolic syndrome-associated conditions and age 50
years also increased the OR for androgen deﬁciency
(Table 3).
Low-risk Patients
We also performed a logistic regression assessing risk of
androgen deﬁciency among 304 subjects having a BMI
<30, no diabetes, no hypertension, and no hyperlipidemia
(Table 4). Among these men, subjects on long-acting opi-
oids had odds of androgen deﬁciency 5.78 times that of
subjects on short-acting opioids. However, subjects on
short-acting opioids had 24% greater odds of androgen
deﬁciency for every 10-mg increase in MSE, as compared
with 2% greater odds in subjects taking long-acting opioids.
DISCUSSION
The ﬁnding that duration of action is inversely related to
testosterone levels in men on opioids initially seems coun-
terintuitive. The standard approach to opioid management
has long focused on switching patients who use opioids
daily to a long-acting formulation to achieve more stable
blood levels of drug and therefore, in theory, better pain
control.18,19 There is, however, no evidence that long-acting
opioids are either more efﬁcacious or safer than their short-
acting counterparts.20-24
Sustained serum drug levels may be responsible for
the increased incidence of androgen deﬁciency in men onlong-acting opioids. Because testosterone is produced in
men in response to pulsatile secretion of gonadotropin-
releasing hormone (GnRH) and then luteinizing hormone
(LH), it is possible that a serum drug level exists above
Table 4 Adjusted Odds Ratios for Androgen Deﬁciency in
Patients with BMI <30, No Diabetes, No Hypertension, and
No Hyperlipidemia
Odds Ratio
Conﬁdence
Interval
Duration of action
Long (vs short) 5.78 2.44-13.67
Dose
10-mg increase, short duration 1.24 1.07-1.44
10-mg increase, long duration 1.02 1.00-1.03
Age (in years) 1.01 0.99-1.04
BMI ¼ body mass index.
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these pulses is inadequate to maintain normal testosterone
levels. By contrast, short-acting opioids have serum drug
levels that may rise and fall several times a day. It may be
that short-acting opioids halt normal testosterone produc-
tion during peak levels, but there is sufﬁcient “trough” time
during each day to allow some GnRH-LH-testosterone
cycles to complete and thereby to maintain testosterone
levels above our threshold of 250 ng/dL. We name this
concept the “nadir hypothesis”: the idea that stable serum
drug levels may prevent normal endocrine function and
that intermittent nadirs in drug levels allow testosterone to
be produced normally, at least during these nadirs. Sup-
porting this idea, a single MSE of morphine suppresses
gonadal function in rats for a period of about 4 hours,
roughly equivalent to one half-life of the drug.25 If
morphine were dosed every 6 hours, then there might well
be a recovery of testosterone production between hours
4 and 6 that would allow levels to return to normal. Inter-
mittent testosterone production may be adequate to main-
tain normal total testosterone levels in men. Our ﬁnding that
each 10-mg increase in MSE among subjects using exclu-
sively short-acting opioids was associated with a higher
odds of androgen deﬁciency than the odds associated with
each 10-mg increase in MSE among subjects using long-
acting opioids provides additional support for this hypoth-
esis. As the MSE of a short-acting opioid increases, there
may be less time during a 24-hour period when nadir serum
levels are reached, either because doses are taken at closer
and closer intervals until they basically approach contin-
uous delivery or because the higher doses produce higher
peaks in serum levels, leaving less time to reach an ade-
quate nadir before the next dose is consumed. If short-
acting opioids are consumed before drug levels from the
prior dose have fallen, the short-acting opioid in effect
mimics a long-acting opioid. The fentanyl patch is a perfect
example of this: it is a very short-acting opioid with near-
continuous delivery in patch form that makes the drug
perform like a long-acting opioid, providing stable rather
than ﬂuctuating drug levels.
In this large cohort of men on chronic daily opioid
therapy for chronic pain, we have shown that long-actingopioids are associated with a greater odds ratio of
androgen deﬁciency than equivalent doses of short-acting
opioids. Additionally, we were able to examine the effects
of several other comorbidities that are associated with
androgen deﬁciency, including hyperlipidemia, hyperten-
sion, and diabetes,15 but it is not known whether these
morbidities are causative. Indeed, recent investigations point
to a bidirectional relationship, whereby androgen deﬁciency
levels lead to higher sugars, lipids, and blood pressure in
men, and these comorbidities in turn lower testosterone.9,26
In the current study, when we controlled for these comor-
bidities, and when we examined a subset of patients without
these diagnoses, duration of action remained the most sig-
niﬁcant contributor to androgen deﬁciency. Age was not a
signiﬁcant factor when we evaluated men with no metabolic
syndrome indicators. Although testosterone can decline with
age, many men maintain normal testosterone levels into
advanced age.27 In this population of men on opioids, it is
possible that age does not play a signiﬁcant role or that the
effect of the opioids exerts a greater inﬂuence on testos-
terone than age and therefore any inﬂuence of age is masked
by opioid use.
Recently, the awareness of androgen deﬁciency in men
on opioids has increased. Several studies have shown that
this occurs frequently in men who use opioids daily, and this
effect can happen quickly and can be profound, although it
is usually reversible if the opioid medications are
removed.1,28,29 Because opioids remain a cornerstone in the
treatment of many types of pain, elucidating the risks and
deﬁning circumstances under which those risks are more
likely to occur is crucial.Strengths and Limitations
The strength of this study is the size, which allowed us to
develop a robust model that controlled for the comorbidities
that are most commonly associated with androgen deﬁ-
ciency in men.
However, a limitation is that, because testosterone levels
are still not routinely tested in the primary care environment,
the subjects may have been symptomatic and may have
asked for, or been offered, a total testosterone level test; as
such, they may not be representative of all patients on daily
opioids. However, unlike what we would expect in a pri-
marily symptomatic population, the incidence of androgen
deﬁciency in this study is actually lower than that reported
in many previous studies, including our previous study of
men seen in a tertiary pain clinic.4,30-32
Although opioids have been postulated to affect testos-
terone at the level of the hypothalamus (GnRH),33 the pi-
tuitary (LH),34,35 and the testes directly,36 we do not have
sufﬁcient evidence from this retrospective study to speculate
at which point in the hypothalamic-pituitary-gonadal axis
opioids are affecting testosterone levels.
We also did not look at race in this study. Although the
incidence of prostate cancer is higher in African American
populations, in at least one study there was no difference in
1200 The American Journal of Medicine, Vol 127, No 12, December 2014incidence of androgen deﬁciency between races.37 We also
did not look at depression, which has been linked to
androgen deﬁciency in men, although, as with metabolic
syndrome, the direction of this relationship is unknown. The
link between depression and androgen deﬁciency should be
investigated further.
As in any retrospective study, we cannot be sure that
the subjects were taking their medications as prescribed.
Because KPNC is a closed system and all patients in this
study received their medications from our pharmacy, we can
calculate the possession rate (days of medication dispensed
based on the medication instructions vs days between reﬁlls)
as a proxy for MSE. Also, because opioids are dependence
forming, most patients on these medications do take them
every day and at regular intervals. Finally, although we
excluded patients with cancer diagnoses from our cohort, we
cannot be sure that all men in this cohort were taking opi-
oids for noncancer pain.CONCLUSION
In a large retrospective study of 1585 men taking opioids
daily for noncancer pain, the duration of action was strongly
associated with androgen deﬁciency even when accounting
for or eliminating comorbidities such as obesity, diabetes,
hypertension, and hyperlipidemia. MSE does play a role but
seems to be more strongly associated with androgen deﬁ-
ciency among men who use exclusively short-acting opi-
oids. Future prospective studies are needed to further
elucidate the relationship between duration of action and
androgen deﬁciency and to clearly identify the mechanism
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